Skip to main content

James Hollingshead

Equibles does not estimate personal net worth.

Get an email with a short summary when Resmed Inc publishes a filing, an earnings call transcript or a press release.

Get RMD alerts

About James Hollingshead

Earlier roles on record: Board Member and CEO at Insulet Corp (PODD) until April 28, 2025. The proxy statement of Insulet Corp reports total compensation of $13,224,270 for James Hollingshead in fiscal 2025, including a base salary of $357,492. Disclosed compensation is on record for 4 fiscal years. James Hollingshead has spoken on 2 earnings calls across 1 company, most recently for Insulet Corp on May 9, 2024. Resmed Inc is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other companies whose calls James Hollingshead spoke on are classified in the Healthcare sector. Other leadership on record at Resmed Inc includes Michael J. "Mick" Farrell (Chairman), Aaron Bloomer (CFO and Board Member), Mike Rider (General Counsel) and 7 others.

James Hollingshead on recent calls

“Coming out of 2023 that saw Insulet emerge as the clear industry leader, we entered 2024 with significant momentum. We were off to a great start in Q1, fueled by continuing strong demand for Omnipod 5.”
CEO, Insulet Corp Q1 FY2024 Earnings Call ·
“In Q2, we enjoyed another quarter of sustained strong momentum, and we remain on track for another successful and transformative year.”
CEO, Insulet Corp Q2 FY2023 Earnings Call ·

Affiliation history

Company network

Current role

Medical Instruments & Supplies · Healthcare

Leadership on record at Resmed Inc

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Insulet Corp (PODD) $357,492 $13,224,270
2024 Insulet Corp (PODD) $930,769 $13,302,350
2023 Insulet Corp (PODD) $842,308 $12,379,765
2022 Insulet Corp (PODD) $440,000 $10,817,028

Recent activity